Policy The finding, achieved with weekly injections of the GLP-1 receptor agonist semaglutide (Wegovy, Ozempic) in the multicenter SELECT trial, establishes overweight/obesity as a modifiable risk factor for CVD, according to lead investigator A
GLP-1 Medications & Hair Loss: How Studio W Salon Can Help If youre currently taking GLP-1 medications and noticing thinning hair or shedding, youre not alone
Who pays the ultimate price
While research on Mounjaro and alcohol is still being conducted, a recent large-scale analysis of patient records in Sweden showed a potential impact of a similar GLP-1 weight-loss injection, semaglutide (Wegovy), and alcohol intake
Steinbrenner and Brigelius-Floh, 2015), the brain and brain disease (Schweizer et al., 2004